How is Ilumya administered?
Ilumya is given as by subcutaneous injection, which means under the skin. Ilumya must be administered by a healthcare professional who will choose an injection site with clear skin and easy access, such as your abdomen (stomach), thighs, or upper arm. Ilumya should not be administered within 2 inches of the navel or where the skin is tender, bruised, red, or affected by psoriasis. It should also not be injected into scars, stretch marks, or blood vessels.
The first two injections of Ilumya are given 4 weeks apart, followed by an injection thereafter once every 12 weeks. Each single-dose prefilled syringe of Ilumya contains 100 mg of tildrakizumab-asmn. Ilumya cannot be self-administered.
In March 2018, the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).
Read next
What are IL-23 Inhibitors and how do they work?
IL-23 inhibitors represent a class of biologic medications that target interleukin-23 (IL-23), a key inflammatory cytokine that plays a central role in driving immune system dysfunction.
Continue reading
Skyrizi vs Ilumya. What’s the difference?
There are a number of differences between Skyrizi and Ilumya:
- Ilumya was FDA approved in 2018 and Skyrizi was FDA approved in 2019.
- Ilyumya is a brand name for tildrakizumab and Skyrizi is a brand name for risankizumab
- The dose of Skyrizi is 150mg, but because each injection only contains 75mg, two injections must be given per dose. The dose of Ilumya is 100mg, and each injection contains 100mg therefore only one injection needs to be given each time
- Ilumya needs to be administered by a healthcare professional; however, patients prescribed Skyrizi can be taught how to self-administer it at home
- Skyrizi is also approved to treat adults with active psoriatic arthritis (PsA), Crohn's disease, and ulcerative colitis.
Does Ilumya treat psoriatic arthritis?
Ilumya is not approved by the FDA to treat psoriatic arthritis, but studies for this use are ongoing. Illumya is only approved to treat plaque psoriasis at this time. Your doctor may decide, based on their medical judgement, to prescribe Ilumya off-label for other conditions.
Continue readingSee also:
Related medical questions
- How does Ilumya compare to other treatments?
- How does Ilumya work to treat psoriasis?
- How long does it take Ilumya to work?
- How does Ilumya affect my immune system?
- What are the side effects of Ilumya?
- What are the new drugs for plaque psoriasis?
- How does Tremfya work?
- Where should you not use triamcinolone acetonide cream?
- Sotyktu vs Otezla: How do they compare?
- Halobetasol vs. clobetasol - How do they compare?
- What are 7 key Stelara side effects to watch out for?
- Does taking vitamin D help with psoriasis?
- What are IL-17 Inhibitors and how do they work?
- What are 6 key Taltz side effects to watch out for?
- What causes Plaque Psoriasis?
- What's the dosing schedule for Skyrizi?
- How long does it take for Otezla to work?
- How do you inject Humira?
- How to stop taking Otezla?
- Cosentyx vs Humira: How do they compare?
- Does Cosentyx cause weight gain or loss?
- What is the mechanism of action of infliximab?
- What happens if Cosentyx is not refrigerated?
- How long does Cimzia take to work?
- Does Skyrizi cause cancer?
- How long does Cosentyx take to work?
- Can Enstilar be used on the scalp?
- Who makes Otezla and why is it so expensive?
- Is Otezla (apremilast) an immunosuppressant?
- How long does it take for Tremfya to work?
Drug information
- Ilumya Information for Consumers
- Ilumya prescribing info & package insert (for Health Professionals)
- Side Effects of Ilumya (detailed)
- Ilumya user reviews (8)
Related support groups
- Ilumya (10 questions, 3 members)
- Plaque Psoriasis (96 questions, 69 members)